Company · Healthcare
Melbourne, VIC
Every investor coverage indicates participated in a round The Alfred Hospital raised.
Companies The Alfred Hospital acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Tom Kelly | Vascular Surgery Registrar (former) | Forbes Australia |
Stories naming The Alfred Hospital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Arovella Therapeutics has produced its first clinical batch of ALA-101, a donor-derived cell therapy for blood cancer, and begun trials at a Melbourne hospital, with the first patient expected to be dosed this month.
Profile tracing Sara Prickett's path from UK labs to co-founding Aravax, the peanut-allergy biotech Brandon Capital backed, as its Phase II trial nears readout in mid-2026.
The federal MRFF has granted $50 million to the Artificial Heart Frontiers Program, a Monash-led consortium including BiVACOR, to advance a total artificial heart; the team earlier received $1 million in 2021.
Also @AuManufacturing
Roundup covering Victorian zero-emission bus trials, Frew Foods' planned plant expansion, 5B's layoffs and completed capital raise, Wellnex Life's convertible note raising, SafetyCulture investing in Inauro, plus wind farm and university research news.
Briefs cover a Bundaberg bioHub development, Incannex's approved sleep apnoea trial, Saber Astronautics winning a US grant for its de-orbit tether, and Next Science's September $10 million raise.
Heart device company Sunshine Heart added cardiologists Marc Silver and David Kaye to its medical advisory board in mid-2006, expanding a panel that guides work on its C-Pulse heart failure treatment.
Sunshine Heart appoints Victor Windeyer as chief operating officer to lead its Australian operations and C-Pulse clinical trials from Sydney; the company also cites a secured grant and ethics approvals at two Melbourne hospitals.
Also GBS Ventures
ASX-listed medical device company Sunshine Heart appointed Melbourne heart transplant specialist Professor Don Esmore to its medical advisory board, which already includes academics from Penn State, Stanford and the Cleveland Clinic.